CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer
therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer
cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1
study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118
with sorafenib for subjects with advanced hepatoma.